April 22, 2019
The Japanese health ministry is expected to give an official stamp of approval as early as June for Eli Lilly’s EGFR antagonist necitumumab, known as Portrazza, and the country’s first Avastin (bevacizumab) biosimilar by Pfizer after they cleared a key...read more